Literature DB >> 23893883

Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing.

Nuha M Alkhawajah1, Joel Oger.   

Abstract

We define late-onset myasthenia gravis (LOMG) when symptoms appear at ≥65 years of age. There has been a continuous increase in the incidence of LOMG with a clear male predominance. Commonly, patients present with focal (ocular or bulbar) weakness. A high index of suspicion required to achieve early diagnosis and to improve prognosis. Management options include acetylcholinesterase inhibitors, steroids, and immunosuppressants. The most controversial issue in treatment is thymectomy, because not enough data are available. Successful treatment is associated with improved survival, and death is often secondary to comorbidities.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  late onset; myasthenia gravis; older adults; thymectomy; treatment

Mesh:

Year:  2013        PMID: 23893883     DOI: 10.1002/mus.23964

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  13 in total

1.  Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity.

Authors:  Roberto Massa; Giulia Greco; Manuela Testi; Emanuele Rastelli; Chiara Terracciano; Erica Frezza; Matteo Garibaldi; Girolama A Marfia; Franco Locatelli; Nicola B Mercuri; Eugenio Pompeo; Giovanni Antonini; Marco Andreani
Journal:  J Neurol       Date:  2019-02-11       Impact factor: 4.849

2.  [Clinical and paraclinical profile of autoimmune myasthenia gravis in Ouagadougou, Burkina Faso].

Authors:  Djingri Labodi Lompo; Nagaonlé Éric Some; Adja Mariam Ouedraogo; Rodrigue P Yonli; Ousséini Diallo; Christian Napon; Athanase Millogo; Jean Kabore
Journal:  Med Trop Sante Int       Date:  2021-11-11

3.  HLA-DQB1*05:02, *05:03, and *03:01 alleles as risk factors for myasthenia gravis in a Spanish cohort.

Authors:  Maria Salvado; Jose Luis Caro; Cecilia Garcia; Francesc Rudilla; Laura Zalba-Jadraque; Eva Lopez; Elia Sanjuan; Josep Gamez; Jose Manuel Vidal-Taboada
Journal:  Neurol Sci       Date:  2022-05-06       Impact factor: 3.830

4.  Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.

Authors:  Ayşın Kısabay; Hüseyin Nezih Özdemir; Figen Gökçay; Neşe Çelebisoy
Journal:  Acta Neurol Belg       Date:  2021-02-05       Impact factor: 2.396

Review 5.  Neuromuscular issues in systemic disease.

Authors:  Wolfgang Grisold; Anna Grisold
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 6.030

6.  Life-threatening misdiagnosis of bulbar onset myasthenia gravis as a motor neuron disease: How much can one rely on exaggerated deep tendon reflexes.

Authors:  Keivan Basiri; Behnaz Ansari; Ali Asghar Okhovat
Journal:  Adv Biomed Res       Date:  2015-02-23

Review 7.  A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature.

Authors:  Maria Elena Farrugia; John A Goodfellow
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

8.  Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care data.

Authors:  Iain M Carey; Emma Banchoff; Niranjanan Nirmalananthan; Tess Harris; Stephen DeWilde; Umar A R Chaudhry; Derek G Cook
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

Review 9.  Myasthenia gravis: a clinical-immunological update.

Authors:  Sophie Binks; Angela Vincent; Jacqueline Palace
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

Review 10.  Complicating autoimmune diseases in myasthenia gravis: a review.

Authors:  Aliona Nacu; Jintana Bunpan Andersen; Vitalie Lisnic; Jone Furlund Owe; Nils Erik Gilhus
Journal:  Autoimmunity       Date:  2015-04-27       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.